West Paces Advisors’s GSK GSK Stock Holding History

West Paces Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-428	Closed	-$20.4K	–	598
2021 Q3	$20.4K	Buy	+428	New	+$21.5K	0.01%	285

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

West Paces Advisors's GSK Position: Q4 2021 in Review

West Paces Advisors sold out of GSK (GSK) in Q4 2021, closing a stake of 428 shares — an estimated $20.4K sold.

West Paces Advisors first reported a position in GSK in Q3 2021 and held it in 1 quarter. The position peaked at $20.4K in Q3 2021. 919 funds tracked by Wall St. Rank hold GSK as of Q4 2021.

West Paces Advisors reported no remaining GSK position as of Q4 2021 after selling out during the quarter.
West Paces Advisors sold 428 GSK shares in Q4 2021, an estimated $20.4K.
West Paces Advisors first reported a position in GSK in Q3 2021 and held it in 1 quarter.
West Paces Advisors's GSK position peaked at $20.4K in Q3 2021.
919 funds tracked by Wall St. Rank held GSK as of Q4 2021.

Based on West Paces Advisors's 13F filing for Q4 2021, filed 20 Dec 2023.